NDAORALTABLET
Approved
Jan 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
TASMAR (tolcapone) by Bausch + Lomb is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 1998.
Drug data last refreshed 11h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TASMAR (tolcapone) is an oral small-molecule catechol O-methyltransferase (COMT) inhibitor approved in 1998 for Parkinson's disease. It extends the duration of levodopa effect by inhibiting the breakdown of dopamine in the peripheral nervous system. The drug is indicated as adjunctive therapy to levodopa/carbidopa in patients with motor fluctuations.
$0.201MPart D
LOE ApproachingDeclining
Minority share within COMT inhibitor class; STALEVO combination products dominate with ~$547K combined spending vs. $201K for TASMAR
Product is in mature/declining phase with minimal claims volume; brand team is likely small or operating in legacy support mode.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)
Started Oct 2018
10 enrolled
Transthyretin AmyloidosisAmyloidosis, Leptomeningeal, Transthyretin-Related
A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone
Started Jun 2018
12 enrolled
Healthy Volunteers
Career Relevance
TASMAR represents a legacy product opportunity with limited career expansion potential; roles are primarily focused on maintaining market share in declining territory and managing patient compliance rather than growth. Professionals joining the TASMAR team should expect transition-oriented responsibilities and may benefit from concurrent exposure to pipeline assets or other Bausch + Lomb franchises.
Worked on TASMAR at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.